Cargando…

Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand

Serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might contribute to confirming the suspected coronavirus disease 2019 (COVID-19) in patients not detected with molecular assays. Human antibodies that target the host angiotensin-converting e...

Descripción completa

Detalles Bibliográficos
Autores principales: Tandhavanant, Sarunporn, Koosakunirand, Sirikamon, Kaewarpai, Taniya, Piyaphanee, Watcharapong, Leaungwutiwong, Pornsawan, Luvira, Viravarn, Chantratita, Narisara
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354433/
https://www.ncbi.nlm.nih.gov/pubmed/34375345
http://dx.doi.org/10.1371/journal.pone.0255796
_version_ 1783736590716108800
author Tandhavanant, Sarunporn
Koosakunirand, Sirikamon
Kaewarpai, Taniya
Piyaphanee, Watcharapong
Leaungwutiwong, Pornsawan
Luvira, Viravarn
Chantratita, Narisara
author_facet Tandhavanant, Sarunporn
Koosakunirand, Sirikamon
Kaewarpai, Taniya
Piyaphanee, Watcharapong
Leaungwutiwong, Pornsawan
Luvira, Viravarn
Chantratita, Narisara
author_sort Tandhavanant, Sarunporn
collection PubMed
description Serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might contribute to confirming the suspected coronavirus disease 2019 (COVID-19) in patients not detected with molecular assays. Human antibodies that target the host angiotensin-converting enzyme 2-binding domain of the viral spike protein are a target for serodiagnosis and therapeutics. This study aimed to characterize the classes and subclasses of antibody responses to a recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients and investigated the reactivity of these antibodies in patients with other tropical infections and healthy individuals in Thailand. ELISAs for IgM, IgA, IgG and IgG subclasses based on RBD antigen were developed and tested with time series of 27 serum samples from 15 patients with COVID-19 and 60 samples from pre-COVID-19 outbreaks including acute dengue fever, murine typhus, influenza, leptospirosis and healthy individuals. Both RBD-specific IgA and IgG were detected in only 21% of the COVID-19 patients in the acute phase. The median IgA and IgG levels were significantly higher in the convalescent serum sample compared to the acute serum sample (P < 0.05). We observed the highest correlation between levels of IgG and IgA (rho = 0. 92). IgG1 and IgG3 were the major IgG subclasses detected in SARS-CoV-2 infection. Only acute IgG3 level was negatively associated with viral detection based on RT-PCR of ORF1ab gene (rho = -0.57). The median IgA and IgG levels in convalescence sera of COVID-19 patients were significantly higher than healthy individuals and convalescent sera of other febrile infectious patients. The analyses of antibody classes and subclasses provide insights into human immune responses against SARS-CoV-2 during natural infection and interpretation of antibody assays.
format Online
Article
Text
id pubmed-8354433
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-83544332021-08-11 Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand Tandhavanant, Sarunporn Koosakunirand, Sirikamon Kaewarpai, Taniya Piyaphanee, Watcharapong Leaungwutiwong, Pornsawan Luvira, Viravarn Chantratita, Narisara PLoS One Research Article Serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) might contribute to confirming the suspected coronavirus disease 2019 (COVID-19) in patients not detected with molecular assays. Human antibodies that target the host angiotensin-converting enzyme 2-binding domain of the viral spike protein are a target for serodiagnosis and therapeutics. This study aimed to characterize the classes and subclasses of antibody responses to a recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients and investigated the reactivity of these antibodies in patients with other tropical infections and healthy individuals in Thailand. ELISAs for IgM, IgA, IgG and IgG subclasses based on RBD antigen were developed and tested with time series of 27 serum samples from 15 patients with COVID-19 and 60 samples from pre-COVID-19 outbreaks including acute dengue fever, murine typhus, influenza, leptospirosis and healthy individuals. Both RBD-specific IgA and IgG were detected in only 21% of the COVID-19 patients in the acute phase. The median IgA and IgG levels were significantly higher in the convalescent serum sample compared to the acute serum sample (P < 0.05). We observed the highest correlation between levels of IgG and IgA (rho = 0. 92). IgG1 and IgG3 were the major IgG subclasses detected in SARS-CoV-2 infection. Only acute IgG3 level was negatively associated with viral detection based on RT-PCR of ORF1ab gene (rho = -0.57). The median IgA and IgG levels in convalescence sera of COVID-19 patients were significantly higher than healthy individuals and convalescent sera of other febrile infectious patients. The analyses of antibody classes and subclasses provide insights into human immune responses against SARS-CoV-2 during natural infection and interpretation of antibody assays. Public Library of Science 2021-08-10 /pmc/articles/PMC8354433/ /pubmed/34375345 http://dx.doi.org/10.1371/journal.pone.0255796 Text en © 2021 Tandhavanant et al https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
spellingShingle Research Article
Tandhavanant, Sarunporn
Koosakunirand, Sirikamon
Kaewarpai, Taniya
Piyaphanee, Watcharapong
Leaungwutiwong, Pornsawan
Luvira, Viravarn
Chantratita, Narisara
Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand
title Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand
title_full Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand
title_fullStr Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand
title_full_unstemmed Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand
title_short Longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (RBD) of SARS-CoV-2 in COVID-19 patients in Thailand
title_sort longitudinal analysis to characterize classes and subclasses of antibody responses to recombinant receptor-binding protein (rbd) of sars-cov-2 in covid-19 patients in thailand
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8354433/
https://www.ncbi.nlm.nih.gov/pubmed/34375345
http://dx.doi.org/10.1371/journal.pone.0255796
work_keys_str_mv AT tandhavanantsarunporn longitudinalanalysistocharacterizeclassesandsubclassesofantibodyresponsestorecombinantreceptorbindingproteinrbdofsarscov2incovid19patientsinthailand
AT koosakunirandsirikamon longitudinalanalysistocharacterizeclassesandsubclassesofantibodyresponsestorecombinantreceptorbindingproteinrbdofsarscov2incovid19patientsinthailand
AT kaewarpaitaniya longitudinalanalysistocharacterizeclassesandsubclassesofantibodyresponsestorecombinantreceptorbindingproteinrbdofsarscov2incovid19patientsinthailand
AT piyaphaneewatcharapong longitudinalanalysistocharacterizeclassesandsubclassesofantibodyresponsestorecombinantreceptorbindingproteinrbdofsarscov2incovid19patientsinthailand
AT leaungwutiwongpornsawan longitudinalanalysistocharacterizeclassesandsubclassesofantibodyresponsestorecombinantreceptorbindingproteinrbdofsarscov2incovid19patientsinthailand
AT luviraviravarn longitudinalanalysistocharacterizeclassesandsubclassesofantibodyresponsestorecombinantreceptorbindingproteinrbdofsarscov2incovid19patientsinthailand
AT chantratitanarisara longitudinalanalysistocharacterizeclassesandsubclassesofantibodyresponsestorecombinantreceptorbindingproteinrbdofsarscov2incovid19patientsinthailand